Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Opus Genetics, Inc. before investing.

In this article, we go over a few key elements for understanding Opus Genetics, Inc.’s stock price such as:

• Opus Genetics, Inc.’s current stock price and volume
• Why Opus Genetics, Inc.’s stock price changed recently
• Upgrades and downgrades for IRD from analysts
• IRD’s stock price momentum as measured by its relative strength

About Opus Genetics, Inc. (IRD)

Before we jump into Opus Genetics, Inc.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Opus Genetics, Inc., a clinical-stage biopharmaceutical company, develops gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs) and other types of therapies for additional ophthalmic disorders. It develops OPGx-LCA5, an early-onset retinal degeneration that is in Phase 1/2 clinical trial for the treatment of LCA5-associated IRD; and OPGx-BEST1 to treat BEST1-associated retinal disease. The company also develops various pre-clinical IRD programs, including OPGx-RHO, a gene therapy that targets autosomal dominant retinitis pigmentosa caused by RHO mutations; OPGx-RDH12 that is designed to restore protein expression and halt functional deterioration in patients with retinal dystrophy caused by mutations in the retinal dehydrogenase gene; OPGx-MERTK, an AAV vector for the treatment of MERTK IRD; OPGx-NMNAT1, a gene augmentation therapy designed to halt functional deterioration in pediatric patients with retinal degenerative disease caused by mutations in the nicotinamide mononucleotide adenylyltransferase 1 gene; and OPGx-CNGB1, an AAV gene therapy for retinitis pigmentosa due to mutations in the CNGB1 gene. In addition, it develops Phentolamine Ophthalmic Solution for reversal of mydriasis, as well as for the treatment of presbyopia and dim light or night vision disturbances and APX3330, a small-molecule inhibitor of Ref-1 for the treatment of diabetic retinopathy. Opus Genetics, Inc. was formerly known as Ocuphire Pharma, Inc. and changed its name to Opus Genetics, Inc. in November 2020. The company was founded in 2018 and is headquartered in Durham, North Carolina.

Want to learn more about Opus Genetics, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Opus Genetics, Inc..

Opus Genetics, Inc.’s Stock Price as of Market Close

As of November 13, 2026, 2:46 PM, CST, Opus Genetics, Inc.’s stock price was $3.975.

Opus Genetics, Inc. is down 2.09% from its previous closing price of $4.060.

During the last market session, Opus Genetics, Inc.’s stock traded between $3.800 and $4.170. Currently, there are approximately 101.84 million shares outstanding for Opus Genetics, Inc..

Opus Genetics, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Opus Genetics, Inc. Stock Price History

Opus Genetics, Inc.’s (IRD) price is currently up 8.31% so far this month.

During the month of November, Opus Genetics, Inc.’s stock price has reached a high of $4.520 and a low of $3.610.

Over the last year, Opus Genetics, Inc. has hit prices as high as $7.070 and as low as $1.700. Year to date, Opus Genetics, Inc.’s stock is up 97.76%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Opus Genetics, Inc. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

One of the most common factors that can drastically impact a stock’s price is analyst upgrades and downgrades. When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. However, as of November 12, 2026,, no analysts have changed their rating of Opus Genetics, Inc.’s stock over the last month.

Additionally, you'll want to evaluate Opus Genetics, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Opus Genetics, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Opus Genetics, Inc.’s current valuation based on AAII’s Value Grade is a F, which means it is considered to be Ultra Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Opus Genetics, Inc. (IRD) by visiting AAII Stock Evaluator.

Relative Price Strength of Opus Genetics, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of November 12, 2026, Opus Genetics, Inc. has a weighted four-quarter relative price strength of 22.29%, which translates to a Momentum Score of 96 and is considered to be Very Strong.

Want to learn more about how Opus Genetics, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Opus Genetics, Inc. Stock Price: Bottom Line

As of November 13, 2026, Opus Genetics, Inc.’s stock price is $3.975, which is down 2.09% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Opus Genetics, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.